Omega Therapeutics reports Q3 results

seekingalpha
2024-11-15
  • Omega Therapeutics press release (NASDAQ:OMGA): Q3 net loss of $16.4M, compared to $22.2M for the third quarter of 2023.
  • The decrease in net loss was driven predominantly by the decrease in R&D and G&A expenses.
  • Revenue of $2.61M (vs. $831K in Q3 2023).
  • As of Sept. 30, 2024, the company had cash and cash equivalents totaling $30.4M, which is expected to fund operations into Q2 2025.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10